Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ceronco Biosciences
Den Haag ("The Hague"), South Holland, Netherlandspitchbook.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ceronco Biosciences is developing anti-cancer drugs using its proprietary SCS technology, which enhances the delivery and efficacy of chemotherapeutic agents by targeting tumor cell membranes. The lead program, CB001—a liposomal doxorubicin enriched with SCS—has shown promise in preclinical studies. Additional candidates are under development based on this platform[2].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeLiposomal drug formulation
- Industry
- Biotech
Beyond the preview
Go deeper on Ceronco Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ceronco Biosciences.